ClinicalTrials.gg
Active, not recruitingNCT06568003Updated Mar 2, 2026

TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)

An interventional study of Transcatheter Tricuspid Valve Intervention in Tricuspid Regurgitation (TR), sponsored by Jenscare Innovation Inc.. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Jenscare Innovation Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Tricuspid Valve Insufficiency with a site in United States — 27 open to participants now, 36 under way, none of them phase 3. Tricuspid Valve Insufficiency · United States.

Planned enrollment
34th of 42
15 · median 63
Started
2024
with 7 others
No phase
39 of 60
18 open now
Primary completion
2025-10
later than 4 of 35 live
Registered
47th of 60
by date
Lead sponsor
2 of 60
Jenscare Innovation Inc.

Among the 60 studies in Tricuspid Valve Insufficiency with a site in United States, this one is the 34th largest by planned enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2024, is one of 39 with no phase, reaches primary completion later than 4 of the 35 other live ones, and was the 47th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

27 of the 60 studies in Tricuspid Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Tricuspid Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The LuX-Valve Plus System is intended for the treatment of patients with at least severe TR who are symptomatic and determined by a Heart Team not to be suitable for surgical treatment. This study aims to assess the safety and effectiveness of the LuX-Valve Plus System in high-surgical risk patients with at least severe tricuspid regurgitation (TR).

Read the detailed description

Investigational Device:

The LuX-Valve Plus System consists of the following elements:

  1. a bioprosthetic valve consistent of bovine pericardial tissue mounted on a self-expanding nitinol stent frame (hereafter referred to as LuX-Valve Implant).The LuX-Valve Implant consists of a trileaflet bovine-pericardial-tissue valve, a nitinol self-expanding stent, a fabric skirt, a pair of clips, an anchoring pin and sutures.
  2. a catheter-based delivery system (hereafter referred to as LuX-Valve Delivery Device),
  3. an Introducer Kit for transvenous access, and
  4. a delivery system Stabilizer.

    • The LuX-Valve Implant sizes:

      o JS/TTVI-28-40, JS/TTVI-28-45, JS/TTVI-28-50, JS/TTVI- 28-55, JS/TTVI-30-40, JS/TTVI-30-45, JS/TTVI-30-50, JS/TTVI-30-55, JS/ TTVI-30-60, JS/TTVI-30-65

    • LuX--Valve Plus Delivery System

      o JS/TTVDJ-33

    • Introducer Kit

      o JS/SID01-33-100

    • Stabilizer o JS/STA-TJ01-01

Primary Objective:

To assess the safety and effectiveness of the LuX-Valve Plus System in patients with at least severe tricuspid regurgitation (TR) who are at high risk for surgical treatment.

Study Sites and Geography:

Up to 3 centers in the United States.

Number of Subjects:

Up to 15 subjects will be enrolled.

Indications for Use:

The LuX-Valve Plus System is intended for the improvement of health status in patients with at least severe TR who are symptomatic and determined by a Heart Team to be at high risk for surgical treatment.

03

Conditions studied

  • Tricuspid Regurgitation (TR)

Keywords

  • Tricuspid Regurgitation
  • Transvenous Tricuspid Replacement
  • LuX-Valve Plus System
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at time of consent
  • Severe or greater TR assessed on transthoracic echocardiography by Echocardiography Core Lab using a 5-grade classification (Mild, Moderate, Severe, Massive, Torrential).
  • (NYHA) Class II-IV
  • The Patient is being treated on optimal dosage for diuretics at investigator discretion
  • The Site Heart Team concur the patient is not an optimal candidate for surgical treatment and it is anatomically suitable for transcatheter tricuspid valve replacement
  • Patient must be able to fully understand all aspects of the investigation that are relevant to the decision to participate and provide a written
  • Anatomical inclusion criteria confirmed by echocardiographic core lab, CT core lab and Eligibility Committee

Exclusion criteria

Exclusion Criteria:

  • (LVEF) \<35%
  • Pulmonary arterial systolic pressure (PASP) >60 mmHg by echo Doppler (unless right heart catheterization [RHC] demonstrates PASP ≤60mmHg); or Right heart catheterization OR PASP >2/3 systemic BP with PVR >5 Wood units after vasodilator challenge, in the absence of symptomatic hypotension or systolic BP \<90 mmHg.
  • Evidence of intracardiac mass, thrombus, or vegetation
  • Ebstein Anomaly or congenital right ventricular dysplasia
  • Surgical correction is indicated for other concomitant valvular disease (subjects with concomitant valvular disease may treat their respective valve first and wait 2 months before being reassessed for the trial)
  • Patients with valve prostheses implanted in the tricuspid valve
  • Pre-existing prosthetic valve(s) (other than tricuspid ones) with prosthetic dysfunction
  • Active infection, infective endocarditis or sepsis within 3 months, or infections requiring antibiotics treatment within two weeks prior to planned procedure
  • Untreated clinically significant coronary artery disease requiring revascularization
  • Acute myocardial infarction or unstable ischemia-related angina within 30 days prior to the planned procedure
  • Any percutaneous coronary, intracardiac or carotid intervention within 30 days prior to the planned procedure
  • Any coronary or intracardiac or carotid intervention within 30 days prior to the planned procedure
  • Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support TRINITY-US Trial #: Ver 1.0, 14 Nov 2023, Confidential Page 7 of 8
  • Cerebrovascular stroke (ischemic or bleeding) within prior 3 months to enrollment
  • Active peptic ulcer or active gastrointestinal bleeding within prior 3 months to enrollment
  • Blood dyscrasias as defined: leukopenia (WBC \<1000 mm3), thrombocytopenia ( count \<50,000 cells/mm3), history of bleeding diathesis, or coagulopathy
  • Inability to tolerate anticoagulation or antiplatelet therapy
  • Severe liver failure
  • Renal insufficiency ( \<30 mL/min [per the formula] and/or renal replacement therapy)
  • Uncontrolled atrial fibrillation (e.g., resting heart rate >120 bpm)
  • Pregnancy or intent to become pregnant prior to completion of all protocol follow-up requirements
  • Severe requiring or requiring continuous home oxygen
  • Untreatable or to any of the following: all antiplatelets, all anticoagulants, nitinol alloys (nickel and titanium), bovine tissue, glutaraldehyde, or contrast media
  • Estimated \<12 months.
  • Subjects currently participating in another clinical trial of an drug or device that has not yet completed its primary endpoint
  • Patients with current history of illicit drug use
  • Any other condition making it unlikely the patient will be able to complete all protocol procedure and follow-ups determined by the investigator
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    : LuX-Valve Plus transvenous tricuspid valve and delivery system(LuX-Valve Plus System)

    The LuX-Valve Plus System is intended for the treatment of patients with severe TR who are determined by a Heart Team to be at high risk of traditional open-heart surgery.

    Device: Transcatheter Tricuspid Valve Intervention

Interventions

  • DeviceTranscatheter Tricuspid Valve Intervention

    Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.

06

What researchers measure

Primary outcomes

  1. Primary Outcome - Post-procedural TR Remission Rate

    Defined as: Post-procedural TR of moderate or less (TR≤2+) without clinically significant paravalvular leak (PVL) on a transthoracic echocardiography (TTE) at 30 days post- procedure (Assessed by the Echocardiography Core Lab using a 5-grade classification)

    Time frame: at 30 days post procedure

  2. Primary Outcome - Incidence of major adverse events at 30 days post procedure

    A composite endpoint of Major Adverse Event (MAE) at 30 days post procedure, as listed below: * Cardiovascular Death * Myocardial Infarction (MI) * Stroke * New Onset Renal Failure Requiring Unplanned Dialysis or Hemofiltration * Major Bleeding (includes type 3b or higher as defined by Tricuspid Valve Academic Research Consortium \[TVARC\]) * Tricuspid Valve Surgery or Transcatheter Re-intervention post Procedure * Major Access Site and Vascular Complications * Major Cardiac Complications * Device-related Pulmonary Embolism * New Pacemaker Implantation due to Atrioventricular (AV) Block

    Time frame: at 30 days post procedure

Secondary outcomes

  1. Acute Secondary Endpoints - Intraprocedural success Rate

    Subjects in whom all of the following were present were considered intraprocedural success, otherwise they were considered intraprocedural failure: * Absence of intraprocedural mortality or stroke; and * Successful access, delivery, and retrieval of the device delivery system * Successful deployment and correct positioning of the intended device without requiring implantation of unplanned additional device * Adequate performance of the transcatheter device. Absence of tricuspid stenosis (TVA ≥1.5cm2 or TVAi≥0.9cm2/m2), DVI\<2.2, mean gradient \<5mmHg; reduction of total tricuspid regurgitation to acceptable (moderate \[2+\]) * Absence of device-related obstruction of forward flow * Absence of device-related pulmonary embolism * Freedom from emergency surgery or reintervention during the first 24h related to the device or access procedure

    Time frame: the first 24h post-procedure

  2. Acute Secondary Endpoints - Clinical success Rate

    Subjects in whom all of the following were present were considered clinical success: * Absence of procedural mortality and stroke * Proper position of the device with adequate performance of the transcatheter device. Absence of tricuspid stenosis (TVA≥1.5cm2 or TVAi≥0.9cm2/m2), DVI\<2.2, mean gradient\<5mmHg; reduction of total tricuspid regurgitation to moderate \[2+\] * Freedom from unplanned surgical or interventional procedures related to the device or access procedure * Absence of MAEs, including: 1. Life-threatening bleeding (TVARC 5) 2. Major vascular complications 3. Major cardiac structural complications 4. Stage 2 or 3 acute kidney injury (includes new dialysis) 5. Myocardial infarction or coronary ischemia requiring percutaneous coronary intervention or coronary artery bypass graft. 6. Device-related obstruction of forward flow 7. Device-related pulmonary embolism 8. Hemodynamic compromise leading to heart transplantation or major cardiac

    Time frame: at 30 days and at 1 year post-procedure

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Oct 2025, 12 months.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's 12 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2024
First posted
Aug 23, 2024
StartActual
Sep 26, 2024
Primary completionActual
Oct 2, 2025
CompletionEst.
Oct 2030
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06568003
Lead sponsor
Jenscare Innovation Inc.
Collaborators
Cardiovascular Research Foundation, New York
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Sep 26, 2024
Primary completion
Oct 2, 2025
Completion
Oct 2030 (estimated)
Last update
Mar 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion